Results 91 to 100 of about 2,544,276 (249)

Valproic acid toxicokinetics: Serial hemodialysis and hemoperfusion

open access: yes, 1999
The toxicity and pharmacokinetic properties of a drug determine whether hemodialysis and/or hemoperfusion are indicated in acute intoxications. Valproic acid is considered unremovable by hemodialysis because of the high protein binding of 90%-95%.
Go, G   +6 more
core   +1 more source

Neuroconnectivity and valproic acid: The myelin hypothesis

open access: yes, 2012
Neuropsychiatric medications that directly alter the epigenome, such as valproic acid, can under certain conditions reactivate critical developmental periods and thus impact adult neuroconnectivity. In animal models valproic acid was shown to inhibit the
Vukadinovic, Zoran   +3 more
core   +1 more source

Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). II. Treatments in more advanced clinical development

open access: yesEpilepsia, EarlyView.
Abstract This article summarizes data for 13 investigational treatments for which at least preliminary seizure outcome data in patients with epilepsy were reported at the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices held in Madrid, Spain, on May 3–6, 2026.
Meir Bialer   +7 more
wiley   +1 more source

Decrease in the effectiveness of valproic acid against the background of antibacterial therapy with imipenem/cilastatin in pediatric practice: A case report

open access: yesСибирский научный медицинский журнал
A clinical case of the co-medication of valproic acid and cilastatin/imipenem in a 17-year-old girl with generalized tonic-clonic seizures is described.
A. B. Strok   +3 more
doaj   +1 more source

Valproic Acid Induced Hyperammonemia in a Long Time Treated Patient

open access: yesCase Reports in Psychiatry, 2016
We report a case of a patient who had been on long time valproic acid for treatment of bipolar affective disorder. While being an inpatient, serology ammonia level testing revealed a very high ammonia level despite being asymptomatic.
Rohit Aiyer   +2 more
doaj   +1 more source

Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). I. Treatments in preclinical and early clinical development

open access: yesEpilepsia, EarlyView.
Abstract Over the last 34 years, the Eilat Conference on New Antiepileptic Drugs and Devices has provided an interactive forum for stakeholders to discuss investigational and recently licensed treatments for seizures and epilepsy. The Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII) took place in Madrid, Spain, on May 3 ...
Meir Bialer   +7 more
wiley   +1 more source

Valproic Acid and Thrombocytopenia

open access: yes, 1996
The association of thrombocytopenia (TCP) with valproic acid (VPA) therapy was evaluated retrospectively in 167 children treated with VPA between 1989 and 1993 at the Department of Pediatrics, Henry Ford Medical Center, Detroit ...
J Gordon Millichap
core   +1 more source

Unveiling Thrombocytopenia Trends In Pediatric Epilepsy: The Valproate Connection

open access: yesJournal of Rawalpindi Medical College
Objective: To determine the frequency and association of thrombocytopenia in patients on valproate therapy in the Pediatrics department of Pakistan Atomic Energy Hospital, Islamabad.
Kiran Nayab   +5 more
doaj   +1 more source

Cardiovascular events and mortality in adults with late onset seizures: Focus on enzyme‐modulating antiseizure medications

open access: yesEpilepsia, EarlyView.
Abstract Objective Using a Dutch insurance claims registry, we examine whether people with epilepsy have an increased risk of major ischemic cardiovascular events or death compared to people without epilepsy. We also assess whether this risk differs between users of enzyme‐modulating and non‐enzyme‐modulating antiseizure medications (ASMs).
Paola Vassallo   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy